LOGIN  |  REGISTER
Cue Biopharma
Compass Therapeutics

Eli Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement

July 25, 2023 | Last Trade: US$773.29 8.19 1.07

INDIANAPOLIS, July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2023 financial results on Tuesday, Aug. 8, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

The conference call will begin at 9 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.

About Lilly

Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn. F-LLY

Refer to:       

Jordan Bishop; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-473-5712 (Media)

 

Joe Fletcher; This email address is being protected from spambots. You need JavaScript enabled to view it.; 317-296-2884 (Investors)

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page